Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Pepscan Continues to Supply Personalized Peptide Pools for Evaxion’s Upcoming Phase IIb Trial After Successful Completion of Phase I/IIa

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Pepscan, the all-in-one peptide service provider with proprietary constraining technologies, is excited to announce that its specialists will manufacture the personalized peptide pools for the treatment of cancer patients in Evaxion’s phase IIb trial.

Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, recently published the initial results of the peptide-based personalized therapy EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. Pepscan had provided the personalized peptide pools for its phase I/IIa trial. The Denmark-based biotechnology company is currently preparing its phase IIb study, which is expected to start in 2022 at various sites in Europe, the US and Australia.

“We are very excited to learn that the personalized peptides we manufactured for Evaxion have induced positive effects in cancer patients treated in the clinic. We consider our collaboration with Evaxion to be a perfect example of how combining Evaxion’s expertise in the development of AI-driven immunotherapies and Pepscan’s track record in the reliable supply of personalized peptide pools brings us closer to potential life-improving breakthroughs,” says Hans de Backer, CEO of Pepscan. “We are very pleased to continue to work with Evaxion on the next phase of its clinical journey.”

The paper, entitled “Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma”, outlines results from the phase I/IIa trial of EVX-01, a novel personalized cancer immunotherapy based on Evaxion’s proprietary PIONEER AI technology. Results from five patients in the study demonstrated that EVX-01 is safe and has encouraging early indications of clinically meaningful antitumor activity. Evaxion’s planned phase IIb study will evaluate the efficacy and safety of EVX-01 in combination with KEYTRUDA® (pembrolizumab), an anti-PD1 therapy, in approximately 100 adults naïve to checkpoint inhibitor treatment with unresectable or metastatic melanoma, with overall response as the primary endpoint.

Manufacturing personalized peptides for neoantigen vaccines requires a very specific set of process development and manufacturing skills, facilities, and analytical methods. With 25 years of experience in mastering peptides and flexible manufacturing capabilities, Pepscan reliably delivers individual or pooled peptide sets that fit its customers’ timelines.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine